Jump Financial LLC Invests $3.78 Million in Vaxcyte, Inc. $PCVX

Jump Financial LLC acquired a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 100,100 shares of the company’s stock, valued at approximately $3,780,000.

Other large investors also recently made changes to their positions in the company. Rhumbline Advisers boosted its holdings in Vaxcyte by 5.5% during the first quarter. Rhumbline Advisers now owns 181,230 shares of the company’s stock worth $6,843,000 after purchasing an additional 9,416 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in Vaxcyte by 5.8% during the first quarter. PNC Financial Services Group Inc. now owns 9,600 shares of the company’s stock worth $362,000 after purchasing an additional 524 shares during the last quarter. Parallel Advisors LLC boosted its holdings in Vaxcyte by 203.6% during the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company’s stock worth $61,000 after purchasing an additional 1,071 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in Vaxcyte by 75.4% during the first quarter. Envestnet Asset Management Inc. now owns 96,600 shares of the company’s stock worth $3,648,000 after purchasing an additional 41,517 shares during the last quarter. Finally, Deutsche Bank AG boosted its holdings in Vaxcyte by 5.6% during the fourth quarter. Deutsche Bank AG now owns 1,212,706 shares of the company’s stock worth $99,272,000 after purchasing an additional 64,522 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cowen restated a “buy” rating on shares of Vaxcyte in a report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $136.50.

Vaxcyte Price Performance

Shares of PCVX stock opened at $30.45 on Tuesday. The stock has a market cap of $3.95 billion, a P/E ratio of -7.41 and a beta of 1.21. The company has a fifty day moving average price of $33.56 and a two-hundred day moving average price of $43.70. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.10). During the same quarter in the previous year, the business posted ($1.10) EPS. As a group, equities research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.